- Home
- KLRS vs VERU Comparison
KLRS vs VERU Comparison
Compare KLRS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- VERU
- Stock Information
- Founded
- KLRS 2019
- VERU 1971
- Country
- KLRS United States
- VERU United States
- Employees
- KLRS N/A
- VERU N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- VERU Health Care
- Exchange
- KLRS Nasdaq
- VERU Nasdaq
- Market Cap
- KLRS 46.0M
- VERU 54.6M
- IPO Year
- KLRS N/A
- VERU 1990
- Fundamental
- Price
- KLRS $4.78
- VERU $2.56
- Analyst Decision
- KLRS Strong Buy
- VERU Strong Buy
- Analyst Count
- KLRS 3
- VERU 3
- Target Price
- KLRS $21.50
- VERU $33.33
- AVG Volume (30 Days)
- KLRS 107.9K
- VERU 201.6K
- Earning Date
- KLRS 11-13-2025
- VERU 12-15-2025
- Dividend Yield
- KLRS N/A
- VERU N/A
- EPS Growth
- KLRS N/A
- VERU N/A
- EPS
- KLRS N/A
- VERU N/A
- Revenue
- KLRS N/A
- VERU $16,886,419.00
- Revenue This Year
- KLRS N/A
- VERU N/A
- Revenue Next Year
- KLRS N/A
- VERU N/A
- P/E Ratio
- KLRS N/A
- VERU N/A
- Revenue Growth
- KLRS N/A
- VERU 337.24
- 52 Week Low
- KLRS $2.14
- VERU $2.42
- 52 Week High
- KLRS $23.69
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- KLRS 47.17
- VERU 28.86
- Support Level
- KLRS $4.67
- VERU $2.46
- Resistance Level
- KLRS $5.10
- VERU $2.71
- Average True Range (ATR)
- KLRS 0.41
- VERU 0.26
- MACD
- KLRS -0.03
- VERU -0.17
- Stochastic Oscillator
- KLRS 39.41
- VERU 7.54
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.